palmOne and PHT Declare Record Year With 20,000 Handheld eDiaries Deployed for Use in Clinical Trials

by Reads (6,679)

MILPITAS, Calif. and CHARLESTOWN, Mass. — palmOne, Inc. and PHT Corporation, the market-leading provider of electronic patient reported outcome (ePRO) solutions used in more than 150 trials worldwide, achieved a record year in 2004 by deploying approximately 20,000 handheld electronic patient diaries for use in clinical trials. To date, PHT has shipped more than 40,000 LogPad Systems, using palmOne devices, to thousands of subjects and clinical research sites in 46 languages and 48 countries around the globe since 2000.

PHT is palmOne’s largest healthcare customer, and has implemented its market-leading LogPad System on multiple palmOne devices, including the m500, m515, Tungsten W, and Tungsten T3 handhelds.

“Our customers prefer to use palmOne devices for eDiaries because they are easy to learn, reliable and intuitive to use — all of which encourage subject compliance,” said Phil Lee, PHT president and chief executive officer. “We believe the escalating demand for our integrated ePRO solutions is supported by a significant increase in market adoption. A rapidly growing number of biopharmaceutical companies are beginning to realize the benefits ePRO provides, including improved data quality, reduced variance and real-time access to data. Working with palmOne has successfully positioned us to meet this increased demand.”

Advantages offered by palmOne devices include extended battery life, a flexible operating system, fast performance, durability and wireless capabilities, such as GSM or Bluetooth technologies. More than one-third of all trials implemented by PHT in 2004 used Wireless LogPads in geographic areas where the underlying cellular telecommunications infrastructure is more reliable or available than analog.

“We’re pleased to maintain such a strong relationship with PHT,” said Jason Barton, director of business and healthcare sales for palmOne. “We’re effecting positive change for healthcare with innovative hardware solutions featuring enhanced screen resolution, more memory and faster processors, Bluetooth, Wi-Fi and wide area network wireless connectivity, all grounded in our patient-friendly user interface. Together with PHT, we will continue to facilitate important clinical research programs worldwide.”

To learn more about this announcement from palmOne and PHT, please visit Booth No. 307 at the Clinical Trials Congress, Feb. 23-25, in Philadelphia (Loews Hotel).

About PHT Corporation

PHT Corporation is the market-leading provider of electronic patient reported outcome (ePRO) solutions used in over 150 trials worldwide. More than 50 biopharmaceutical and medical device companies, including 13 of the top 15 drug development firms in the world, rely on PHT’s innovative and comprehensive ePRO solutions for their Phase I-IV clinical studies. PHT’s integrated Product Suite enables successful clinical trials by improving data quality, reducing data variance, and providing real-time access and analysis of the data collected. PHT has experience with more than 60,000 subjects at 8,000 clinical sites in 46 languages and 48 countries around the globe. PHT, a pioneer in developing innovative technology to meet clinical research’s evolving needs, is headquartered in Charlestown, MA, and Geneva, Switzerland. For more information, please visit

About palmOne, Inc.

palmOne, Inc. — a leader in handheld computing and communications solutions — strives to put the power of computing in people’s hands so they can access and share their most important information. The company’s products include Treo smartphones, Zire and Tungsten handhelds, and software and accessories.

palmOne products are sold through select Internet, retail, reseller and wireless operator channels throughout the world, and at palmOne Retail Stores and palmOne online stores (

More information about palmOne, Inc. is available at



All content posted on TechnologyGuide is granted to TechnologyGuide with electronic publishing rights in perpetuity, as all content posted on this site becomes a part of the community.